Marvin Gee

• Leveraging advanced peptide-HLA discovery platforms to identify disease-driving antigens and previously inaccessible targets, expanding the range of therapeutic opportunities beyond conventional immune-cell surface markers
• Exploring multiple strategies for selectively targeting peptide-HLA complexes, including T-cell engagers and other precision immune-modulating approaches, to enhance specificity while minimizing off-target immune effects
• Presenting case studies highlighting the discovery, validation, and therapeutic potential of novel peptide-HLA targets, demonstrating how precision antigen recognition can enable the next generation of autoimmune disease therapies

As autoimmune T-cell engager development moves beyond first-generation approaches, the field is increasingly focused on identifying which immune-cell populations and biological pathways will deliver the safest, most selective, and most durable therapeutic responses.

In this interactive roundtable session, attendees will break into smaller discussion groups to evaluate the opportunities, challenges, and translational considerations associated with three of the most important target classes shaping the future of autoimmune T-cell engager development. Each group will discuss one of the following areas:

• Broad B-cell lineage markers, exploring the advantages and limitations of targeting widely expressed B-cell populations to achieve deep immune-cell depletion, rapid disease control, and scalable therapeutic applicability across multiple autoimmune indications
• Plasma cell reservoirs, discussing strategies to eliminate long-lived pathogenic plasma cells that may drive chronic disease persistence and relapse, while balancing infection risk, immune preservation, and long-term safety considerations
• Autoreactive antigen-specific B cells, evaluating emerging precision approaches designed to selectively target diseasedriving immune-cell populations while minimizing off-target immune depletion and preserving broader immune competence